Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

@article{Treon2014CarfilzomibRA,
  title={Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr{\"o}m's macroglobulinemia.},
  author={Steven P P Treon and Christina K. Tripsas and Kirsten E Meid and Sandra Kanan and Patricia Sheehy and Stacey Chuma and Lian Xu and Yanglin Cao and Guang Yang and Xia Liu and Christopher J. Patterson and Diane L Warren and Zachary R. Hunter and Barry Turnbull and Irene M. Ghobrial and Jorge J. Castillo},
  journal={Blood},
  year={2014},
  volume={124 4},
  pages={
          503-10
        }
}
Bortezomib frequently produces severe treatment-related peripheral neuropathy (PN) in Waldenström's macroglobulinemia (WM). Carfilzomib is a neuropathy-sparing proteasome inhibitor. We examined carfilzomib, rituximab, and dexamethasone (CaRD) in symptomatic WM patients naïve to bortezomib and rituximab. Protocol therapy consisted of intravenous carfilzomib, 20 mg/m2 (cycle 1) and 36 mg/m(2) (cycles 2-6), with intravenous dexamethasone, 20 mg, on days 1, 2, 8, and 9, and rituximab, 375 mg/m(2… 
View on PubMed
jorgejcastillo.com
136 Citations
Highly Influential Citations
7
Background Citations
33
Methods Citations
7
Results Citations
3

136 Citations

Citation Type

Citation Type

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia
TLDR
IDR offers a highly effective and well tolerated, neuropathy-sparing regimen for primary therapy in patients with WM, and with a median follow-up of 22 months, the median progression-free survival was not reached.
Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia
TLDR
A 53-year-old man with severe debilitating neuropathy after treatment with CaRD developed progressively worsening severe lower extremity pain with profound weakness requiring treatment with oral gabapentin and hydromorphone, and treatment was changed to bendamustine/rituximab.
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
TLDR
DRC is an effective and well‐tolerated salvage regimen for WM, and in contrast to ibrutinib, DRC offers a less expensive, fixed‐duration option, with preliminary data suggesting efficacy independent of the patients’ MYD88 status.
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
TLDR
IDR provides a safe and effective frontline treatment option for symptomatic patients with WM and the safety profile was excellent with no grade 4 adverse events or deaths to date.
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
TLDR
Combination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM and quality of life improved significantly after induction.
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström’s macroglobulinemia
TLDR
Carfilzomib-based regimens are well tolerated and offer a neuropathy sparing approach with excellent responses both in newly diagnosed MM and WM making them a good choice for the frontline treatment of these diseases.
Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation
TLDR
The ibrutinib-rituximab combination is both effective and safe, in the newly-diagnosed and relapsed-refractory disease setting, and the optimal therapeutic approach for WM patients remains however to be established.
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
TLDR
It is concluded that dexamethasone must be associated to bortezomib-based regimen because of the high variability in overall response rate and median progression-free survival in patients with advanced Waldenström macroglobulinemia.
Current options to manage Waldenström’s macroglobulinemia
TLDR
Despite encouraging results, Waldenström’s macroglobulinemia remains an incurable disease; therefore, new treatment options are needed and continued participation in clinical trials should be encouraged.
Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia
TLDR
This review article provides a modern clinical perspective of the individualized management of patients with symptomatic WM, in the context of the updated treatment guidelines and the currently available trial data.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
TLDR
BDR is rapidly acting, well tolerated, and nonmyelotoxic, inducing durable responses in previously untreated patients with Waldenström macroglobulinemia in a phase 2 multicenter trial.
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
TLDR
It is demonstrated that BDR produces rapid and durable responses, along with high rates of response and complete remissions in WM, and alternative schedules for bortezomib administration that includes weekly dosing should be pursued.
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
TLDR
The combination of bortezomib and rituximab has significant toxicity but is effective, particularly in patients with WM, and toxicity and efficacy were equivalent between the two groups.
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
TLDR
A large, multicenter trial showed that the non-stem-cell toxic DRC regimen is an active, well-tolerated treatment for symptomatic patients with Waldenström macroglobulinemia.
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
TLDR
The combination of weekly bortezomib and rituximab exhibited significant activity and minimal neurological toxicity in patients with untreated Waldenström Macroglobulinemia.
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
  • I. Ghobrial, F. Hong, +13 authors J. Matous
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The combination of weekly bortezomib and rituximab showed significant activity and minimal neurologic toxicity in patients with relapsed WM.
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
TLDR
Bortezomib has efficacy in WM, but neurotoxicity can be dose limiting, and the slower response in nodal disease may require prolonged therapy, perhaps with a less intensive dosing schedule to avoid early discontinuation because of toxicity.
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
TLDR
The results of these studies show that bortezomib is an active agent in relapsed and refractory WM and sensory neuropathies resolved or improved in nearly all patients following cessation of therapy.
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
TLDR
The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options.
Maintenance Rituximab is associated with improved clinical outcome in rituximab naı̈ve patients with Waldenstrom Macroglobulinaemia who respond
TLDR
Because of the non-myelosuppressive nature of rituximab, and its potential to synergize with various anti-neoplastic agents including alkylators, nucleoside analogues, immunomodulatory drugs, and proteasome inhibitors, its investigation in combination regimens has been vigorously pursued.
...
1
2
3
4
...